Frankfurt - Delayed Quote EUR

Ocumension Therapeutics (5DG.F)

0.5200

0.0000

(0.00%)

As of 8:05:02 AM GMT+1. Market Open.

Three Growth Companies Insiders Are Investing In

As global markets continue to rally, with U.S. stocks reaching record highs amid optimism for softer tariffs and AI investments, growth stocks have notably outperformed value shares for the first time this year. In such a buoyant market environment, companies with high insider ownership can be particularly appealing as they often signal strong confidence from those closest to the business.

Simply Wall St. yesterday

1477.HK
January 2025's Insider Picks For Leading Growth Companies

As global markets navigate a complex landscape marked by fluctuating consumer confidence and mixed economic signals, major indices such as the Nasdaq Composite have shown resilience with moderate gains. In this environment, growth companies with high insider ownership can be particularly intriguing, as they often reflect strong internal confidence and alignment between management and shareholders.

Simply Wall St. 30 days ago

1477.HK
3 Growth Companies With High Insider Ownership Expecting Up To 39% Revenue Growth

In a week marked by market volatility and shifting investor sentiment due to policy uncertainties from the incoming Trump administration, global indices experienced mixed performances. Amid these fluctuations, growth companies with high insider ownership can offer unique investment insights, as their leadership's vested interest often aligns with shareholder value creation.

Simply Wall St. 2 months ago

EXNWF

1477.HK
Growth Companies With High Insider Ownership On SEHK October 2024

As global markets experience varied economic shifts, Hong Kong's Hang Seng Index has recently faced a downturn amid waning optimism about Beijing's stimulus measures. In this fluctuating environment, growth companies with high insider ownership on the SEHK can offer unique insights into potential resilience and alignment of interests between management and shareholders.

Simply Wall St. 3 months ago

AKESF

1477.HK

VOBIF
OcuMension acquires rights to Alcon eye drops in exchange for a 16.7% equity stake, signaling the commencement of comprehensive strategic relationship

On August 13th 2024, Ocumension Therapeutics ("OcuMension") announced an agreement with Alcon Inc. ("Alcon", and collectively with OcuMension, the "Parties") where OcuMension will acquire or secure commercialization rights in China to a portfolio of Alcon dry eye treatments and procedural drops, including several commercially available products and one development-stage product. The scope of the agreement will also cover areas of R&D, manufacturing and commercialization in China. In connection w

PR Newswire 5 months ago

1477.HK
Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights

On August 12, Ocumension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "Ocumension" or the "Company") released its 2024 Interim Results Report. During the reporting period, the company achieved operating revenue of RMB 168 million, representing a year-on-year increase of 61.6%. The gross margin was 59.2%, and the adjusted loss amounted to RMB 101 million, narrowing by 20.0% year-on-year. This significant growth in performance is attributed to the accelerated advancement

PR Newswire 5 months ago

1477.HK
3 SEHK Stocks Including Ocumension Therapeutics Estimated To Be Trading Below Intrinsic Value

The Hong Kong market has recently experienced mixed performance, with the Hang Seng Index declining by 0.45% amid weak manufacturing data and concerns over domestic demand. This presents a potential opportunity for discerning investors to identify undervalued stocks that may be trading below their intrinsic value. In light of current market conditions, focusing on stocks with strong fundamentals and growth potential can be particularly advantageous. Here are three SEHK stocks, including...

Simply Wall St. 5 months ago

2276.HK

IGGGF

1477.HK
High Insider Ownership Growth Companies On SEHK In July 2024

Amidst a backdrop of global market fluctuations and deepening China-U.S. trade tensions, the Hong Kong market has shown resilience with specific sectors demonstrating robust growth potential. High insider ownership in growth companies on the SEHK signals strong confidence from those who know these companies best, which can be particularly appealing in the current uncertain economic climate.

Simply Wall St. 6 months ago

1477.HK

MPNGF

MPNGY
High Insider Ownership Growth Companies On SEHK In June 2024

Amidst a backdrop of fluctuating global markets, Hong Kong's Hang Seng Index has shown resilience with a modest gain, reflecting investor optimism and robust retail sales growth. In such an environment, stocks with high insider ownership in Hong Kong can be particularly compelling as they often signal strong confidence from those closest to the company's operations.

Simply Wall St. 7 months ago

MEIUF

1477.HK

BYDDF
Exploring Three SEHK Growth Companies With High Insider Ownership

As global markets display mixed signals with some regions grappling with economic uncertainties, the Hong Kong market has not been immune to challenges, evidenced by a notable decline in the Hang Seng Index. In such an environment, growth companies in Hong Kong with high insider ownership can offer a unique appeal, as significant insider stakes often align management’s interests closely with shareholders', potentially fostering greater resilience and long-term strategic focus amidst market...

Simply Wall St. 8 months ago

CASBF

0189.HK

1477.HK
May 2024 SEHK Growth Leaders With High Insider Ownership

As of May 2024, the Hong Kong market is experiencing a notable upswing, with the Hang Seng Index climbing 2.64% recently, reflecting positive investor sentiment amid recovery hopes fueled by robust holiday spending and trade data. This buoyant backdrop sets an intriguing stage for examining growth companies in Hong Kong that boast high insider ownership—a factor often linked with strong corporate governance and aligned interests between shareholders and management.

Simply Wall St. 8 months ago

1477.HK

ADCNF

1501.HK
OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth

On the evening of March 21st, OcuMension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "OcuMension" or the "Company") disclosed its 2023 annual performance report. The company achieved a total operating income of RMB 246.4 million for the full year, a year-on-year increase of 55.0%; with a comprehensive gross profit of RMB 144.4 million, representing a year-on-year increase of 40.3%. During the reporting period, the company's major operating indicators performed well, b

PR Newswire 10 months ago

1477.HK

Performance Overview

Return	5DG.F	HANG SENG INDEX
YTD	-1.89%	+0.92%
1-Year	-9.57%	+28.79%
3-Year	-58.73%	-14.12%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ocumension Therapeutics (5DG.F)

Three Growth Companies Insiders Are Investing In

January 2025's Insider Picks For Leading Growth Companies

3 Growth Companies With High Insider Ownership Expecting Up To 39% Revenue Growth

Growth Companies With High Insider Ownership On SEHK October 2024

OcuMension acquires rights to Alcon eye drops in exchange for a 16.7% equity stake, signaling the commencement of comprehensive strategic relationship

Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights

3 SEHK Stocks Including Ocumension Therapeutics Estimated To Be Trading Below Intrinsic Value

High Insider Ownership Growth Companies On SEHK In July 2024

High Insider Ownership Growth Companies On SEHK In June 2024

Exploring Three SEHK Growth Companies With High Insider Ownership

May 2024 SEHK Growth Leaders With High Insider Ownership

OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth

Performance Overview